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Summary Somatostatin analogues can suppress the secretion of some gastrointestinal hormones and growth
factors involved in the growth regulation of gastrointestinal cancers and can inhibit the growth ofexperiment-
al pancreatic tumours. Therefore, in a phase II study 34 patients with metastatic pancreatic (n = 14), colorectal
(n = 16) and gastric cancer (n = 4) were treated with three daily subcutaneous injections of 100-200 lAg of the
somatostatin analogue Sandostatin (SMS 201-995). All patients had an extensive tumour load and 13 were
pretreated with chemotherapy. Before Sandostatin treatment the patients with pancreatic cancer showed a
higher mean plasma concentration of GH (P<0.05) and a lower concentration of 'total' somatomedin-C
(P<0.005) compared with patients with colorectal cancer; there was no significant difference betwen these two
groups in plasma levels of directly assayable somatomedin-C, EGF/TGF-a, insulin and prolactin. Within 3
days after start of treatment, somatomedin-C levels initially decreased (without a change in basal plasma GH
levels), but returned to pretreatment levels within 4-13 weeks. Plasma insulin levels also were suppressed but
only during the first 3-5 days of treatment. Plasma EGF-TGF-a levels increased significantly at day 5 of
treatment only in the pancreatic cancer patients. Twenty-seven per ceht of the patients showed stable disease
for 3-9 months, but most patients experienced subjective improvement in the absence of serious side-effects.
However, the overall survival remained disappointing, emphasising the need for better treatment regimens.
Several gastrointestinal hormones can stimulate the growth
of exocrine pancreatic and gastrointestinal tumours (John-
son, 1981; Townsend et al., 1981; Viullot et al., 1983;
Lamers, 1987; Lamers & Jansen, 1988; Schally, 1988). The
secretion of these hormones and some growth factors can be
suppressed by somatostatin or its analogues (Adrian et al.,
1981; Schally, 1988). Furthermore, not only normal target
tissues for somatostatin but also tumours from the same
endocrine tissue contain receptors for somatostatin (Reubi et
al., 1987). Recently, we demonstrated clear growth inhibitory
effects of 3 somatostatin analogues on a transplantable rat
acinar pancreatic adenocarcinoma (Klijn et al., 1987, 1988,
1989a) in addition to the presence of specific binding sites for
somatostatin, insulin-like growth factor-I (IGF-1) and
epidermal growth factor (EGF) in these tumours (Klijn et al.,
1989a; Reubi et al., 1988). In view of these data,
we have conducted a phase II study of 34 patients with
metastatic pancreatic and gastrointestinal 'non-endocrine'
adenocarcinomas. The objective of the present study was the
assessment of the antitumour and endocrine effects of
chronic treatment with the potent long-acting somatostatin
analogue Sandostatin (SMS 201-995).
Patients, materials and methods
The study was performed after approval by a local Human
Investigations Committee and by The Netherlands Cancer
Foundation (Protocol number KWF-CKVO 86-3). Thirty-
four patients with metastatic disease (14 with pancreatic
cancer, 16 with colorectal cancer and four with gastric
cancer) gave informed consent to be treated with Sando-
statin. The characteristics of the subgroups of patients are
summarised in Table I. Fourteen patients were pretreated
with chemotherapy. Nearly all patients had metastases in the
liver and/ or the lungs. Twenty-one patients (all with pan-
creatic cancer, six with colorectal and one with gastric
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cancer) already had metastases at the time ofdiagnosis of the
primary tumour. The mean interval between detection of
metastases and start of Sandostatin treatment was 74 and
145 days for the pancreatic and colorectal cancer patients,
respectively.
The patients were treated during the first week with a daily
dose of 3 x 100 fg Sandostatin subcutaneously (s.c) followed
by 3 x 200 ltg per day s.c. from the second week of treatment
until objective tumour progression. The duration of treat-
ment varied from 1.5 to 38 weeks with an average of 10
weeks (Table I). Measurements of tumour response were
performed according to the UICC criteria by at least two
medical doctors including review of all X-rays.
Plasma samples for measurement of hormones (growth
hormone, prolactin, insulin) and growth factors (epidermal
growth factor, somatomedin-C/insulin-like growth factor-i)
Table I Patient characteristics
Pancreatic Colorectal Gastric
cancer cancer cancer
Number of patients 14 16 4
Male 8 11 3
Female 6 5 1
Mean age in years (range) 57 (43-74) 61 (37-78) 60 (54-68)
Site of metastasis
Liver 11 10 1
Lung 1 6
Lymph node 1 2 1
Peritoneum I
Per continuitatem 2 1
Adrenal I 1
Bone
Disease-free intervals in
months
Mean (range) 0.1 (0-1) 16 (0-48) 3 (0-9)
Pretreatment with 3 x 9 x 2 x
chemotherapy
Mean duration range of 7 (15-20) 13 (3-38) 5 (3-8)
treatment with
Sandostatin (weeks)
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were taken before treatment and on days 1, 3, 5 and,7 after
start of treatment, thereafter after 2, 4, 8, 12 and 16 weeks of
treatment in a number of unselected patients (Table II,
Figure 1). Plasma levels of growth hormone (GH), prolactin
(PRL) and insulin were measured by radioimmunoassays as
described before (Klijn et al., 1980; Lamberts et al., 1986).
Plasma levels of somatomedin-C (Sm-C) were measured by
radioimmunoassay using a kit purchased from Nichol's Insti-
tute Diagnostics (San Juan Capistrano, California, USA).
Assays were performed on plasma samples both with ('total'
Sm-C) and without ('direct' Sm-C) prior acid-ethanol ext-
raction (Foekens et al., 1989a). Plasma levels of polypeptides
with EGF/TGFx-like activities were determined with a radio-
receptor assay for EGF after prior precipitation of plasma
proteins with 75% (w/v) (NH4)2SO4 for 1 h at OC, centri-
fugation for 20 min at 20,000g, and redissolving the pellet in
10 mM phosphate buffer (pH 7.6) containing 0.15 M NaCI
(Foekens et al., 1989a,b).
Statistical analysis was performed using the two-tailed
Student's t test and the non-parametric method of Wilcoxon.
Results
Differences in endocrine parameters between subgroups of
patients before treatment
Mean plasma GH level (Table II) was higher (P<0.05) in
patients with pancreatic cancer (4.2 + 1.7jigl-'; mean ±
s.e.m., n = 8) than in patients with colorectal cancer
(1.7 ± 0.3gg 1', n = 16). On the other hand, 'total' Sm-C
concentrations measured after acid extraction were lower
(P<0.005) in the pancreatic cancer patients (1.3 ± 0.3 U
ml-', n = 10) compared to the levels found in plasma of
patients with metastatic colorectal tumours (2.5 ± 0.3 U
ml', n = 16). In contrast, there was no difference in direct
n = 10
mU 1-
c
C
-140-
36-
32-
28-
24 -
20-
16-
12-
8-
Pancreatic cancer
9 8 5 16 15 16 12
XX X
pLg IV1
LL
w cs
co
I
Table II Basal plasma hormone and growth factor concentrations in
patients with metastatic pancreatic and colorectal carcinoma
Pancreatic Colorectal
Assay cancer cancer Difference
GH ugl') 4.2±1.7 (8) 1.7±0.3 (16) P<0.05
'Direct' Sm-C (U ml) 1.2±0.5 (10) 0.7±0.1 (16) n.s.
'Total' Sm-C (Uml-') 1.3±0.3 (10) 2.5±0.3 (16) P<0.005
Insulin (mul-') 17.3±2.5 (8) 28.2±7.4 (16) n.s.
EGF(g l') 3.4±0.3 (10) 3.8±0.3 (16) n.s.
PRL(ugl') 11.9±4.3 (8) 5.9±0.5 (16) n.s.
Results are mean s.e.m. (n).
assayable Sm-C between the 2 groups of patients (Table II).
Also no significant differences were found for plasma insulin,
EGF/TGFa and PRL levels (Table II). The absence of a
difference in direct assayable and acid extracted Sm-C levels
was striking in the pancreatic cancer patients, while the acid
extracted ('total Sm-C') levels were much higher than direct
Sm-C levels in the colorectal cancer patients (Figure 1) as
observed in normals.
Endocrine effects oftreatment
After start of treatment mean plasma GH levels showed a
slight but non-significant decrease in patients with pancreatic
cancer, whereas in patients with colorectal cancer plasma GH
levels remained virtually unchanged (Figure 1). Plasma Sm-C
concentrations decreased in nearly all patients with both
metastatic pancreatic and colorectal tumours. Mean acid-
extracted plasma Sm-C concentration decreased from 1.27 to
0.74 U ml' (0.10>P>0.05) in the pancreatic cancer
patients, and from 2.49 to 1.58 U ml-' (P<0.01) in patients
with colorectal cancer. Direct assayable Sm-C concentration
decreased significantly (P<0.01) only in the group of
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Figure I Plasma concentrations of GH, Somatomedin-C, insulin and EGF/TGFa during chronic treatment with Sandostatin in
patients with metastatic pancreatic or colorectal cancer. *P<0.05, x P<0.01 compared to pretreatment values.
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patients with colorectal cancer, i.e. from 0.68 to 0.41 U ml['
(Figure 1). However, in most patients plasma Sm-C concen-
trations returned to pretreatment levels within 4-13 weeks
after start of treatment.
Plasma insulin levels decreased significantly (Figure 1) both
in patients with pancreatic cancer (P<0.01) and in patients
with colorectal tumours (P<0.05). However, this fall in
mean plasma insulin concentrations was only transient and
pretreatment values were reached again after 5 days of treat-
ment (Figure 1). In general, no significant effects oftreatment
were observed on plasma levels of EGF/TGFa and PRL.
However, in the patients with pancreatic cancer the mean
plasma EGF/TGFa concentration increased significantly
from 3.39 to 4.4fig 1- at day 5 of treatment (Figure 1).
Mean plasma PRL levels varied between 11.0 and 14.0 ig I1
in the pancreatic cancer patients and between 5.2 and
6.6Mg l- in the colorectal cancer patients and did not vary
at different treatment periods.
Antitumour effects
With respect to the antitumour effects, five patients could not
be evaluated for response (Table III) because of early death
(two), loss of follow-up (two), or intercurrent disease (trau-
matic hip fracture). In eight out of 29 evaluable patients
(27%) we observed stable disease (three patients with pan-
creatic, four with colorectal, and one with gastric cancer) for
3-9 months. The other patients showed progressive disease
from the start of treatment. The median survival was 2
months for the pancreatic cancer patients and 8 months for
the colorectal carcinoma patients (Figure 2). However, most
patients experienced temporary subjective improvement with
a decrease in pain.
Table III Antitumour effects of treatment with Sandostatin in 34
patients with metastatic pancreatic and gastrointestinal cancer
CR/PR NC PD Ineval. Total
Pancreatic cancer 0 3 10 1 14
Colorectal cancer 0 4 9 3 16
Gastric cancer 0 1 2 1 4
Total 0 8 (27%) 21 (73%) 5 34
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Figure 2 Survival from start of treatment with Sandostatin in 14
patients with pancreatic cancer ( ) and 16 patients with
colorectal cancer (---). All died.
Side-effects
No serious side-effects were observed. Most patients, not
using morphinomimetric drugs, had one to three bowel
motions a day with soft faeces as a consequence of moder-
ately increased faecal fat loss as measured semi-quantita-
tively, but overall significant loss of body weight did not
occur during the treatment periods. One patient had com-
plaints of severe oesophagitis in the presence of strongly
decreased mobility of the distal part of the oesophagus.
Discussion
Little is known about hormone profiles in groups of patients
with different tumours. In spite of higher GH levels acid-
extracted 'total' Sm-C levels were lower in patients with
pancreatic carcinoma than in patients with colorectal car-
cinoma, whereas directly assayable Sm-C concentrations were
not different. This indicates a low concentration of binding
proteins in patients with pancreatic cancer as a consequence
of anorexia and poor physical condition. Sandostatin treat-
ment caused in both subgroups an immediate decrease of
plasma insulin and Sm-C concentrations, followed by an
escape from this suppressive effect, which can be explained
by downregulation of somatostatin receptors (Lamberts et
al., 1986).
In spite of good tumour growth inhibition by different
somatostatin analogues in experimental models (Schally,
1988; Klijn et al., 1988, 1989a) the antitumour effects ofdaily
injections with the somatostatin analogue Sandostatin in
patients with either metastatic pancreatic or gastrointestinal
tumours appeared disappointing in our present study. These
relatively poor treatment results with Sandostatin might be
explained by different reasons as (1) insensitivity of human
tumours perse for this kind of treatment, (2) lack of somato-
statin receptors in human tumours (Reubi et al., 1988), (3)
lack of indirect tumour growth inhibition caused by insuffic-
ient long-term suppression of hormone or growth factor
secretion, (4) pretreatment with chemotherapy in many
patients and presence of extensive disease in all patients at
the start of Sandostatin therapy.
Most patients showed subjective improvement, especially a
decrease in pain, which improvement might be caused by the
analgetic effect of somatostatin (analogues) (Chrubasik et al.,
1984; Meynadier et al., 1985). The observed slight steatorrhea
is a consequence of the inhibitory effect of somatostatin
(analogue) treatment on exocrine pancreatic and gastrointes-
tinal function (Reichlin, 1983a,b). With respect to potential
future clinical trials, new more powerful analogues or other
treatment schemes, especially with slow release depot prepar-
ations of somatostatin analogues which are more effective
than daily injections, have to be applied as single treatment
while combinations with antisteroidal agents might also be
considered in view of good results in our preclinical studies
(Klijn et al., 1989b).
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